-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Q5XU6HxGnK3PWE0Ohy/LhtTjaI6IMkQqYXk3GPgZUpaldcuxxrtw3E1IZc+3uRMc 4B9nN+WnvFFGURjouQsLmA== 0000950123-08-006622.txt : 20080605 0000950123-08-006622.hdr.sgml : 20080605 20080605171509 ACCESSION NUMBER: 0000950123-08-006622 CONFORMED SUBMISSION TYPE: 15-12B PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20080605 DATE AS OF CHANGE: 20080605 EFFECTIVENESS DATE: 20080605 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sirtris Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001388775 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 201410189 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12B SEC ACT: 1934 Act SEC FILE NUMBER: 001-33465 FILM NUMBER: 08883787 BUSINESS ADDRESS: STREET 1: SUITE 104 STREET 2: 790 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-252-6920 MAIL ADDRESS: STREET 1: SUITE 104 STREET 2: 790 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Sirtris Pharmaceuticals DATE OF NAME CHANGE: 20070202 15-12B 1 y6007915e15v12b.htm FORM 15 15-12B
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number: 001-33465
SIRTRIS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
200 Technology Square
Cambridge, MA 02139
(617) 252-6920
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Common Stock, par value $0.001 per share
(Title of each class of securities covered by this Form)
None
(Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
                 
 
  Rule 12g-4(a)(l)(i)   þ   Rule 12h-3(b)(l)(i)   þ
 
  Rule 12g-4(a)(l)(ii)   o   Rule 12h-3(b)(1)(ii)   o
 
  Rule 12g-4(a)(2)(i)   o   Rule 12h-3(b)(2)(i)   o
 
  Rule 12g-4(a)(2)(ii)   o   Rule 12h-3(b)(2)(ii)   o
 
          Rule 15d-6   o
Approximate number of holders of record as of the certification or notice date:
Common Stock, par value $0.001 per share — 1 holder
Pursuant to the requirements of the Securities Exchange Act of 1934, Sirtris Pharmaceuticals, Inc. has caused this Certification and Notice to be signed on its behalf by the undersigned duly authorized person.
Date: June 5, 2008
             
    SIRTRIS PHARMACEUTICALS, INC.
 
            
    By:   /s/ Christoph Westphal
         
 
      Name:   Christoph Westphal
 
      Title:   President, Chief Executive Officer and Vice Chairman
 
 

 -----END PRIVACY-ENHANCED MESSAGE-----